AbbVie Inc. Capex per Share

Capex per Share of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capex per Share growth rates and interactive chart. Capex per share refers to the total amount of capital expenditures paid in a period divided by the weighted average number of shares outstanding. If a company has capex of $100 million and 10 million shares outstanding, capex per share is $10.


Highlights and Quick Summary

  • Capex per Share for the quarter ending March 30, 2020 was -0.08 (a -23.34% decrease compared to previous quarter)
  • Year-over-year quarterly Capex per Share decreased by -2.43%
  • Annual Capex per Share for 2019 was -0.37 (a -9.98% decrease from previous year)
  • Annual Capex per Share for 2018 was -0.41 (a 24.89% increase from previous year)
  • Annual Capex per Share for 2017 was -0.33 (a 12.26% increase from previous year)
  • Twelve month Capex per Share ending March 30, 2020 was -0.38 (a 3.27% increase compared to previous quarter)
  • Twelve month trailing Capex per Share decreased by -10.99% year-over-year
Trailing Capex per Share for the last four month:
30 Mar '20 30 Dec '19 29 Sep '19 29 Jun '19
-0.38 -0.37 -0.35 -0.43
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capex per Share of AbbVie Inc.

Most recent Capex per Shareof ABBV including historical data for past 10 years.

Interactive Chart of Capex per Share of AbbVie Inc.

AbbVie Inc. Capex per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -0.08
2019 -0.11 -0.1 -0.09 -0.07 -0.37
2018 -0.08 -0.19 -0.07 -0.07 -0.41
2017 -0.11 -0.08 -0.08 -0.06 -0.33
2016 -0.07 -0.07 -0.08 -0.07 -0.3
2015 -0.09 -0.08 -0.07 -0.09 -0.33
2014 -0.1 -0.11 -0.09 -0.09 -0.38
2013 -0.1 -0.08 -0.07 -0.06 -0.31
2012 -0.06 0.01 -0.06 -0.1 -0.21
2011 -0.07 -0.05 -0.06 0.0 -0.23
2010 0.0 -0.28
2009 0.0 0.0

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc., a research-based biopharmaceutical company, develops and markets pharmaceutical products in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a biologic therapy administered as an injection for autoimmune and intestinal diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the treatment of patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; and Janssen Biotech, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.